

Not for release to U.S. wire services or distribution in the United States

ASX ANNOUNCEMENT MARKET RELEASE

14 February 2025

Successful A\$15 million placement

Highlights

- **Binding commitments received for A\$15 million under a two-tranche placement to professional or sophisticated investors (Placement) at A\$0.73 per share (Placement Price).**
- **Placement proceeds to be applied to accelerate regulatory applications for Salix® Coronary Plaque (SCP) & Salix® Coronary Flow (SCF), customer implementation, clinical studies, research & development, regulatory costs & working capital along with commencing a flagship plaque study (SAPPHIRE) to support broad clinical credibility and accelerate commercial adoption of the Salix® Software in new US hospital centres.**

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), is pleased to announce it has received binding commitments for a A\$15 million two tranche placement at A\$0.73 per share.

The Placement supports acceleration of the ongoing commercialisation of the Company's patented AI platform that detects key coronary artery disease imaging markers.

Placement proceeds will be applied to accelerate regulatory applications for Salix® Coronary Plaque (SCP) & Salix® Coronary Flow (SCF), customer implementation, clinical studies, research & development, regulatory costs & working capital along with commencing a flagship plaque study (SAPPHIRE) to support broad clinical credibility and **accelerate** commercial adoption of the Salix® Software in new US hospital centres.

Further information in relation to the Company and Placement is provided in the investor presentation lodged with this announcement.

Petra Capital acted as sole lead manager and sole bookrunner to the Placement.

Artrya CEO Mathew Regan said

"The team is delighted to be raising capital at such an important inflection point in the Company's history. Clearance from the US Food and Drug Administration (FDA) in relation to regulatory approval for the Salix® Coronary Anatomy product is expected in March 2025.

The Company continues the regulatory pathway to expand FDA approvals this year with a portion of Placement proceeds applied to accelerate regulatory applications for our SCP & SCF products, along with customer implementation costs including the Sonic Healthcare Australia Radiology commercial agreement announced on 12 February 2025.

A portion of Placement proceeds will also be applied to commence the SAPPHIRE study, expected to expand the Salix® software to additional centres in the US, providing further credibility for commercial roll out whilst locking the centres into the Company's software.

We look forward to continuing to update the market with our ongoing progress."

Placement Details

The A\$15 million placement, being 20,547,946 shares, will be completed in two tranches at a Placement Price of A\$0.73 per share. The Placement Price represents a 10.4% discount to the 5-day volume weighted average trading price at 11 February 2025.

The Company will issue 6,798,498 shares under tranche one of the Placement (**Tranche One Placement**). Tranche One Placement shares will be issued under the Company's remaining placement capacity (6,716,403 under ASX Listing Rule 7.1 and 82,095 under ASX Listing Rule 7.1A).

The Company will issue 13,749,448 shares, subject to shareholder approval at a general meeting of the Company to be held on or around 2 April 2025, under tranche two of the Placement (**Tranche Two Placement**).

In addition, subject to shareholder approval, the Company will issue 2,054,795 new options to Petra Capital with an exercise price of A\$1.095 and expiry of 2 years from issue.

Tranche One Placement shares are expected to settle on 19 February 2025 with allotment on or around 20 February 2025. Tranche Two Placement shares are expected to settle, subject to shareholder approval, on 7 April 2025 and allot on or around 8 April 2025.

Timetable

The following timetable is indicative only and may be subject to change at the sole discretion of the Company, in consultation with the Lead Manager, and in compliance with the ASX Listing Rules and Corporations Act.

Placement Announcement	14 February 2025
Tranche One Placement Settlement Date	19 February 2025
Tranche One Placement Allotment Date	20 February 2025
General Meeting	On or around 2 April 2025
Tranche Two Placement Settlement Date	7 April 2025
Tranche Two Placement Allotment Date	8 April 2025

This announcement was approved by the Board.

For further information please contact:

Investor Enquiries:

Danny Younis

[+61 420 293 042](tel:+61420293042)

danny.younis@automicgroup.com.au

Media Relations:

Rama Razy

[+61 498 440 142](tel:+61498440142)

rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.